Mounjaro (Tirzepatide)

Mounjaro (Tirzepatide) is an innovative, once-weekly injectable medication designed to help adults with type 2 diabetes manage their blood sugar levels. Developed by Eli Lilly, Mounjaro is the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist — a next-generation therapy that mimics two key incretin hormones to regulate blood sugar and appetite.

By enhancing insulin release, decreasing glucose production in the liver, and slowing gastric emptying, Mounjaro helps lower A1C levels and supports weight loss in many patients. It is typically prescribed alongside a balanced diet and regular exercise and may also contribute to improvements in metabolic health.

Key Features:

• Active ingredient: Tirzepatide

• Indication: Type 2 diabetes mellitus in adults

• Administration: Subcutaneous injection, once weekly

• Mechanism: Dual GIP and GLP-1 receptor agonist for improved insulin sensitivity and appetite control

• Benefits:

  • Significant A1C reduction

  • Clinically proven weight loss support

  • Convenient once-weekly dosing